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Abstract 
Metallo-β-lactamases (MBLs) hydrolyze almost all β-lactam antibiotics and are unaffected by 
clinically available β-lactamase inhibitors (βLIs). Active-site architecture divides MBLs into 
three classes (B1, B2 and B3), complicating development of βLIs effective against all enzymes. 
Bisthiazolidines (BTZs) are carboxylate-containing, bicyclic compounds, considered as 
penicillin analogues with an additional free thiol. Here, we show both L- and D-BTZ 
enantiomers are micromolar competitive βLIs of all MBL classes in vitro, with Kis of 6-15 µM 
or 36-84 µM for subclass B1 MBLs (IMP-1 and BcII, respectively), and 10-12 µM for the B3 
enzyme L1. Against the B2 MBL Sfh-I, the L-BTZ enantiomers exhibit 100-fold lower Kis 
(0.26-0.36 µM) than D-BTZs (26-29 µM). Importantly, cell-based time-kill assays show BTZs 
restore β-lactam susceptibility of E. coli producing MBLs (IMP-1, Sfh-1, BcII and GOB-18) 
and, significantly, an extensively drug resistant Stenotrophomonas maltophilia clinical isolate 
expressing L1. These data therefore show BTZs to inhibit the full range of MBLs, and 
potentiate β-lactam activity against producer pathogens. X-ray crystal structures reveal insights 
into diverse BTZ binding modes, varying with orientation of the carboxylate and thiol moieties. 
BTZs bind the di-zinc centers of B1 (IMP-1; BcII) and B3 (L1) MBLs via the free thiol, but 
orient differently depending upon stereochemistry. In contrast, the L-BTZ carboxylate 
dominates interactions with the monozinc B2 MBL Sfh-I, with the thiol uninvolved. D-BTZ 
complexes most closely resemble β-lactam binding to B1 MBLs, but feature an unprecedented 
disruption of the D120-zinc interaction. Cross-class MBL inhibition therefore arises from the 
unexpected versatility of BTZ binding. 
  
  
 
Significance statement 
Bacterial diseases remain a huge burden on healthcare worldwide, with the emergence and re-
emergence of strains resistant to currently used antibiotics posing an increasing clinical threat. 
Metallo-β-lactamases (MBLs) are key determinants of antibiotic resistance as they hydrolyze 
almost all β-lactam antibiotics and are unaffected by currently available β-lactamase inhibitors 
(βLIs). The structural diversity between MBLs has proved problematic when designing βLIs 
effective against all MBL targets. Here we show a series of small compounds, bisthiazolidines, 
to act as inhibitors of all MBL types, restoring the efficacy of currently used antibiotics against 
resistant bacterial strains producing different MBLs. High-resolution crystal structures reveal 
how diverse MBLs are inhibited by the unexpected versatility of bisthiazolidine binding, 
raising implications for future βLI design. 
 
 
 
  
  
\body 
Introduction 
The production of metallo-β-lactamases (MBLs) by Gram-negative pathogens such as 
Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa 
and Stenotrophomonas maltophilia is a major contributor to bacterial antibiotic resistance (1, 
2). MBLs are able to hydrolyze most β-lactam antibiotics, including clinically important serine 
β-lactamase inhibitors (βLIs, clavulanic acid and penicillanic acid sulfones) and the 
carbapenems, which are often used as a ‘last-resort’ therapy for serious infections (3-6). MBLs 
can be divided into three subclasses, B1, B2 and B3, based on sequence, structure and zinc ion 
utilization (2, 7-9). All three classes contain a similar overall αββα fold, with the active site 
lying in a groove between the two β-sheets (Figure 1). In most di-zinc B1 enzymes, such as 
IMP-1 (10), BcII (11) and NDM-1 (12), the Zn1 site is tetrahedrally coordinated by a water 
molecule (Wat1), H116, H118 and H196 (standard MBL numbering scheme (7) used 
throughout), while Zn2 is bound by Wat1, a second water molecule (Wat2), D120, C221 and 
H263 in a trigonal bipyrimidal coordination. A water molecule (Wat1) bridges/coordinates Zn1 
and Zn2, in an arrangement that is suited to activate it as a nucleophile. 
In mono-zinc B2 enzymes such as CphA (13) and Sfh-I (14), binding of the zinc ion is 
representative of the Zn2 site in B1 enzymes, with coordination by a water molecule (Wat1), 
D120, C221 and H263, in a tetrahedral rather than trigonal bipyrimidal geometry. Two water 
molecules (Wat1 and Wat2) are present in the active site, with Wat2 hydrogen-bonded to H118 
and H196, and Wat1 coordinating Zn2, lying approximately equidistant between Zn2 (2.3 Å) 
and Wat2 (2.6 Å). Wat2 is believed to be activated by H118, rather than a zinc ion, to act as 
the nucleophile during antibiotic hydrolysis (14).  
Di-zinc B3 enzymes (e.g. L1(15) and AIM-1(16)) have similar active-site architectures 
to B1 MBLs, with Zn1 in tetrahedral coordination with a water molecule (Wat1), H116, H118 
and H196; and the nucleophilic water (Wat1) bridging Zn1 (1.9 Å) and Zn2 (2.1 Å). Zn2, 
however, is coordinated by D120, H121, H263 and an additional water molecule (Wat2) in a 
distorted trigonal bipyramidal geometry. To date clinically useful βLIs of any of the three MBL 
classes have not been identified, and the aforementioned structural differences have 
complicated development of βLIs with cross-class (B1, B2 and B3) activity. 
In response to this urgent medical need, we have developed and synthesized four 
bisthiazolidine (BTZ) compounds, L-CS319 (1a), D-CS319 (1b), L-VC26 (2a) and D-VC26 
  
(2b) (blue, gray, orange and cyan, respectively, Figure 2) (17, 18). These novel βLIs contain 
both a free thiol, which is a high affinity zinc-binding group, and two defining properties of 
β-lactam substrates, a feature hitherto overlooked in MBL inhibitor design. These are first a 
carboxylate moiety that in penicillins and carbapenems is able to bind Zn2 and interact with 
conserved residues on the protein main chain (19, 20); and, secondly, a tetrahedral bridgehead 
nitrogen that interacts with Zn2 as hydrolysis of bicyclic β-lactam antibiotics proceeds (21, 22). 
The absence of structural information on how a single compound can bind and inhibit all three 
classes of MBLs hinders further development of any potent cross-class inhibitors. We therefore 
characterized cross-class MBL inhibition in vitro, and in MBL producing bacteria, by the four 
previously synthesised BTZs, and obtained crystal structures for B1 (IMP-1 and BcII), B2 
(Sfh-I) and B3 (L1) MBLs complexed with the novel scaffold, including one compound (1a) 
now structurally characterised in all three classes. These data demonstrate how a single 
compound class can utilize multiple modes of binding to inhibit, in vitro and in producer 
organisms, MBLs of different classes and active-site architectures; and identify routes to 
further improve potency against the range of target enzymes. 
  
  
Results 
BTZs are cross-class MBL inhibitors in vitro 
Previous kinetic characterization of BTZ inhibition of selected MBL targets demonstrated them 
to be micromolar competitive inhibitors of carbapenem (imipenem) hydrolysis by the B1 
MBLs VIM-2 and NDM-1, with Kis varying between 3.7 ± 0.3 and 19 ± 3 µM (17, 18) (Table 
1). Here, we evaluate their cross-class inhibition potential by measuring the in vitro effect of 
BTZs on imipenem hydrolysis by other MBLs of the B1 [Bacillus cereus BcII (11, 23, 24) and 
Serratia marsescens IMP-1 (10)], B2 [Serratia fonticola Sfh-I (14, 25)] and B3 [S. maltophilia 
L1 (15, 26)]. To ensure coverage of diverse MBLs, we also assayed activity against the 
structurally-uncharacterized, atypical Elizabethkingia meningoseptica GOB-18, reconstituted 
in its fully active monozinc form (27). 
These data reveal the compounds to be competitive, micromolar inhibitors of all MBL classes 
(Figures S1 and S2), with Kis between 0.26 ± 0.03 µM and 84 ± 6 µM (Table 1). The inhibition 
of B1 MBLs is little affected by the stereochemistry on the BTZs (D- (1b, 2b) or L- (1a, 2a) 
BTZs), or by the presence of a gem-dimethyl group (2a, 2b), with Ki values varying by 2 and 
2.5-fold (IMP-1 and BcII, respectively). In particular, BTZ potency against IMP-1 is the same 
for both enantiomers, while the addition of a gem-dimethyl group (2a/2b) resulted in a 2-fold 
increase in Ki. In contrast, against BcII, D-BTZs were 1.5 to 2.5-fold less potent than the 
L-BTZs, while the gem-dimethyl group had little effect on potency (2a/2b Ki is up to 1.5-fold 
greater than 1a/1b). Against the B3 MBL L1 all compounds exhibit near identical Ki values, 
between 10 and 12 µM ± 1-2, while only 2b exhibits similar potency against the B3 MBL 
GOB-18 (10 µM), with the three other BTZs 3 to 4-fold less potent (30-41 µM ± 1-4). The 
unusual GOB-18 active site, in which the Zn1 ligand H116 is replaced by Q, and only the Zn2 
site is occupied in vitro (27), likely accounts for these small differences we observe in potency 
against B3 enzymes. While it is possible periplasmic GOB-18 is di-zinc, as GOB-1 (28), 
importantly these data show the BTZ scaffold inhibits MBLs with even highly atypical active-
site architectures. Only against B2 Sfh-I is there strong stereochemical preference, with 
L-BTZs (1a, 2a) greater than 100-fold more potent than their corresponding D-enantiomers 
(1b, 2b). As is the case for the B1 and B3 enzymes, there is little change in BTZ potency on 
addition of a gem-dimethyl group, with 1a and 2a exhibiting similar, submicromolar Ki values 
(0.26 ± 0.03 µM and 0.36 ± 0.04 µM, respectively). 
 
  
BTZs restore β-lactam efficacy towards MBL producing isolates 
To assess the clinical potential of BTZs, time-kill assays were performed using E. coli cells 
expressing the B1 MBLs IMP-1 and BcII, B2 Sfh-I and the B3 enzyme GOB-18 (Figure S3). 
Additionally, a multi-drug resistant S. maltophilia clinical isolate producing both the B3 MBL 
L1 and the serine β-lactamase L2 was also studied (Figure 3 and Figure S4). The βLIs do not 
have any antimicrobial effect on their own, as differences could not be detected in viable cell 
number between cells exposed to BTZs and broth-only controls. Viable cell counts following 
exposure to sub-lethal concentrations of β-lactams (imipenem and ticarcillin-clavulanate for 
the E. coli and S. maltophilia isolates, respectively) in the presence of BTZs demonstrated that 
BTZs are able to inactivate the MBLs in clinically relevant strains, as evidenced by the 
significant reductions in bacterial count (>103). Potentiation of antibiotic activity against S. 
maltophilia is particularly significant as strains of this Gram-negative pathogen tend to be 
extensively multidrug resistant, particularly due to the expression of two distinct β-lactamases 
and several membrane-spanning multidrug efflux pumps (29).  
 
Structure determination of BTZ complexes with B1, B2 and B3 MBLs 
An understanding of how BTZs inhibit all three classes of MBL requires structural information 
for representative BTZ:MBL complexes to complement our previously obtained structures of 
1a bound to the B1 MBLs VIM-2 and NDM-1 (17, 18). We therefore crystallized the MBLs 
IMP-1 and BcII (subclass B1), Sfh-I (B2) and L1 (B3) and soaked the crystals in the four BTZs. 
Co-complex structures were solved for IMP-1 with 1b (2.30 Å resolution) and 2a (2.30 Å); 
BcII with 1b (1.80 Å); Sfh-I with 1a (1.3 Å) and L1 with 1a (1.63 Å), 1b (1.84 Å) and 2b (1.80 
Å) (Table S1). For B2 Sfh-I we were unable to obtain a co-complex with both BTZ 
stereoisomers, consistent with the in vitro observation that D-BTZs were at least 100-fold less 
potent Sfh-I inhibitors than L-BTZs. In all seven cases there was clear Fo-Fc density in the 
MBL active site into which the corresponding ligand could be modelled (Figure S5). Further 
ligand validation statistics (real-space R-value, local ligand density fit and real-space 
correlation coefficient) are presented in Table S2. 
IMP-1 crystallized in the space group P212121, with four molecules in the asymmetric 
unit (ASU), not previously described. Electron density consistent with bound 2a was observed 
in three of the four subunits (average B-factor 1.8 times greater than the protein main chain), 
whereas 1b could be confidently modelled in all four molecules of the ASU (B-factors 1.1 
  
times above main chain). For comparison, we have also solved, to 1.98 Å resolution, the 
structure of uncomplexed di-zinc IMP-1, also in the space group P212121 (see Supplemental 
Information). BcII crystallized in the previously described space group C2 (30), with one 
molecule in the ASU and one molecule of 1b identified in the active site (B-factor 1.6 times 
above main chain). Sfh-I crystallized in space group P21 (14), with 1a clearly defined in both 
monomers of the ASU (B-factors 1.2 times above protein main chain). L1 crystallised in space 
group P6422 (15), with one molecule in the ASU, into which 1a, 1b and 2b were modelled into 
clearly defined density (B-factors 2.1, 1.8 and 1.7 above main chain). Ligands were refined at 
full occupancy for all but L1:1b (ligand occupancy 0.76) and L1:2b (0.81). 
 
A dual-mode of binding for L-BTZs to MBLs. 
The IMP-1:2a (Figure 4A) and L1:1a (Figure 4B) structures reveal similar binding modes for 
L-BTZs to IMP-1 (B1) and L1 (B3) (Figure 4C). These also resemble the previously observed 
binding mode of 1a to both VIM-2 (18) and NDM-1 (17) (Figure S6). In all these structures, 
the thiol of the BTZ mercaptomethyl group is positioned nearly equidistant between the two 
zinc ions (between 2.22 and 2.43 Å ± 0.14 and 0.23 Å; see Table S1 for coordinate errors and 
Table S3 for detailed distances). BTZ-binding displaces the zinc-bridging nucleophilic 
water/hydroxide (Wat1) that is observed in the native MBL active site (Figure S7) with a 
concomitant small increase in the Zn1 - Zn2 distance of c. 0.3/0.4 Å (± 0.14/0.23 Å), compared 
to uncomplexed enzymes (Table S3). L-BTZ-binding is further stabilized by direct interaction 
of its carboxylate with structurally equivalent side chains that are implicated in substrate 
binding (19, 20, 31), K224 in IMP-1 and S223 in L1. 1a also makes hydrophobic interactions 
with two residues on L1 (W38 and P226), and 2a contacts two (W64 and V67) on the flexible 
L3 loop (32) positioned above the IMP-1 active site (gray side chains in Figure 4A and B). 
Despite these similarities, BTZ-binding results in a larger ligand:protein buried surface area in 
the IMP-1:2a (330 Å2) complex compared to L1:1a (264 Å2), largely due to the L3 loop which 
is present in IMP-1 but not L1 (Figure 4). 
In contrast, L-BTZ-binding to the mono-zinc B2 MBL Sfh-I differs substantially from 
that to B1 or B3 enzymes. In the complex with 1a, the 1a-carboxylate group interacts with the 
active-site zinc (1.84 ± 0.03 Å), and is within hydrogen-bonding distance of two protein side 
chains, N233 (2.97 ± 0.03 Å) and H196 (2.96 ± 0.03 Å) (Figure 5A). Binding to Sfh-I results 
in c. 265 Å2 of buried surface area, and is stabilized by interactions with four hydrophobic 
  
residues (W87, F156, I153, F236, gray, Figure 5A). In addition, although BTZ-binding has 
little effect on the overall Sfh-I structure [RMSD 0.33 Å over 228 Cα atoms, compared to 
native Sfh-I (14)] there are significant rearrangements within the active site (Figure 5B). The 
BTZ-carboxylate displaces the water zinc ligand (Wat1), maintaining the tetrahedral zinc 
geometry, and causing a flip and c. 0.6 Å (± 0.03 Å) movement of the H196 side chain. This 
movement results in a loss of interaction of H196-Nε2 with the nucleophilic water (Wat2), 
which moves 0.9 Å deeper into the active site and closer to Zn2 (3.0 Å compared to 3.5 Å in 
uncomplexed Sfh-I, ± 0.03 Å). Notably, and in direct contrast to the structures obtained for 
complexes with IMP-1 and L1, the BTZ thiol is not involved in interactions with the Sfh-I zinc 
site. 
 
A distinct mode of D-BTZ binding to L1 
We next investigated binding of D-BTZ inhibitors to our chosen MBL targets. Surprisingly, 
structural analysis of D-BTZs bound to the B3 enzyme L1 revealed a third mode of binding. 
Similar to the L1:1a complex, the 1b-mercaptomethyl group dominates L1 active-site 
interactions, with the thiol bridging the two zinc ions, again resulting in a small (0.4 ± 0.17 Å) 
increase in the Zn1-Zn2 distance (Table S3). However, the carboxylate group is no longer 
bound to S223, but instead interacts, via a water molecule, with Y32 on the non-conserved N-
terminal extension of L1 (2.74 Å BTZ - water, 2.40 Å water - Y32, ± 0.17 Å, Figure 6A). This 
interaction causes an approximate 90̊ rotation of D-BTZ around the thiol compared to L-BTZ, 
orientating the BTZ to make hydrophobic interactions with three residues (P226, F156, I162, 
Figure 6B) of which only P226 is involved in binding 1a. Despite this, the buried surface area 
on ligand binding is similar in both the L1:1a and L1:1b complexes (264 Å2 and 268 Å2, 
respectively). The structure of L1:2b indicates that the presence of a dimethyl group does not 
affect this mode of binding, although unsurprisingly there is a slight increase in the buried 
surface area (279 Å2). 2b makes the same hydrophobic interactions as 1b (Figure 6C) and is 
bound with similar thiol-zinc and Zn1-Zn2 distances (Table S3). As in the L1:1b structure, 
interaction of the 2b carboxylate with Y32 is also mediated by a water molecule (2.81 Å 2b - 
water, 2.53 Å water - Y32, ± 0.18 Å). 
 
  
  
1b binding to B1 MBLs involves multiple ligand-zinc interactions 
Structures of 1b bound to the B1 enzymes BcII and IMP-1 reveal multiple interactions of the 
inhibitor with both zinc ions in the active site (Figure 7). However, BTZ binding does not 
result in global conformational changes for either IMP-1 (IMP:1b compared to uncomplexed 
IMP-1 RMSD=0.28 Å over 222 Cα atoms) or BcII (BcII:1b compared to uncomplexed BcII 
RMSD=0.41 Å over 223 Cα atoms). 1b binding to IMP-1 (buried surface area 292 Å2) features 
four ligand-zinc interactions (Figure 7A), the carboxylate (2.1 ± 0.26 Å) and bridging nitrogen 
(2.8 ± 0.26 Å) with Zn2, and the thiol bridging Zn1 (2.0 ± 0.26 Å) and Zn2 (2.2 ± 0.26 Å), with 
the Zn1-Zn2 distance increasing by 0.2-0.3 Å (± 0.26 Å). Binding is further favored by 
interaction of the carboxylate with Lys224, as is the case with 2a binding to IMP-1.  
As in the IMP-1:2a complex, residues W64 and V67 in the L3 loop are involved in 
hydrophobic interactions with the inhibitor, with W64 in particular forming π-stacking 
interactions with the BTZ bicyclic ring. Despite previous observations the NDM-1 L3 loop 
may ‘close’ on 1a binding (17), the position of the IMP-1 L3 loop is more stable, with no 
substantial conformational shifts evident on BTZ-binding compared to the native structure.  1b 
makes very similar interactions (Figure 7B) on binding BcII (buried surface area 287 Å2), i.e., 
the carboxylate (2.0 ± 0.13 Å) and bridging nitrogen (2.7 ± 0.13 Å) with Zn2, the carboxylate 
with K224 (2.9 ± 0.13 Å), and the thiol equidistant between active-site zincs (2.2 ± 0.13 Å), 
with the Zn1 - Zn2 distance increasing by 0.3 ± 0.13 Å compared to uncomplexed BcII (PDB 
4C09). Three hydrophobic interactions are formed, one with W87 and two with residues F61 
and V67 in the L3 loop, which form after the L3 loop closes by approximately 3.0-4.6 ± 0.13 
Å compared to its position in the native structure (Figure S8). As observed in the 1a:Sfh-I 
complex, there are also important rearrangements within the IMP-1 and BcII active sites on 1b 
binding (Figure 7C and D). Remarkably, the electron density clearly defines a displacement 
of the Zn2 ligand D120 and consequent loss of the D120-Zn2 coordination interaction (Figure 
S9). Instead, D120 reorients to form hydrogen bonds with either E59 (IMP-1) or S69 (BcII). 
This results in an irregular five-coordinate geometry for Zn2 and a 1.0 ± 0.26 Å (IMP-1) or 0.7 
± 0.13 Å (BcII) movement of Zn2 away from D120. 
  
  
Discussion 
Here we show the structural basis for micromolar competitive inhibition of all three MBL 
classes by BTZs, including of clinically relevant enzymes from opportunist bacterial 
pathogens, such as E. coli, P. aeruginosa or S. maltophilia, which can cause severe or even 
life-threatening infections. BTZs are able to cross the outer membrane of Gram-negative 
bacteria and enter the periplasm, inhibiting MBL activity in vivo and potentiating the activity 
of carbapenems and other -lactams against MBL-producing clinical isolates. Our data 
demonstrate this simple scaffold, which in several aspects resembles the architecture of the 
bicyclic -lactam substrate, is able to overcome the variations in MBL active-site architecture 
across subclasses to achieve roughly equipotent inhibition of all MBLs tested. Such variations, 
which encompass differences in zinc ligands, interaction partners for the carboxylate group at 
C2/C3 of -lactams and the positions and locations of hydrophobic surfaces and 
conformationally flexible surface loops adjacent to the active site, have manifest as substantial 
differences in potency against different MBL targets for some other inhibitor classes. 
Unexpectedly our structural data reveal that BTZ inhibition of different MBLs is unique and 
characterised by multiple binding modes that vary both with target enzyme and with the BTZ 
enantiomer used. 
The crystal structures of MBL:BTZ complexes presented here and in previous 
publications (17, 18) identify that BTZs utilize four distinct modes of binding to the range of 
MBL targets. L-BTZs adopt similar binding modes to the B1 and B3 binuclear enzymes, with 
overall BTZ orientation retained across enzymes that utilize different side chains [K224 (BcII, 
IMP-1, NDM-1); R228 (VIM-2) and S223 (L1)] in interactions with the BTZ carboxylate 
group that may or may not involve the intermediacy of (a) bound water molecule(s). This 
binding mode is also robust to differences in the composition (particularly with respect to the 
positions of aromatic residues) and orientation of the mobile L3 loop that is a feature of most 
B1 MBLs, but absent in B3 enzymes such as L1.  
In contrast, D-BTZ binding differs profoundly between complex structures for B1 
(BcII, IMP-1) and B3 (L1) enzymes, with interactions involving the carboxylate group (with 
Zn2 and the K224 side chain) a feature of the BcII and IMP-1 complexes but absent from those 
with L1. The differing L1 active-site architecture, which compared to B1 MBLs lacks an 
extended L3 loop and instead features elongated linkers between other secondary structural 
elements adjacent to the active site and hydrophobic residues at different positions, likely 
  
imposes a different orientation upon the bound D-BTZ ligand. The fourth binding mode is 
observed in B2 MBL Sfh-I complexed with 1a. In B2 enzymes conserved hydrophobic residues 
on the long α3 helix adjacent to the active site form a ‘hydrophobic wall’ proposed to contribute 
to selective carbapenem binding (33, 34). In the Sfh-I:1b structure, the BTZ thiol was observed 
buried deep into the hydrophobic cavity formed by residues W87, I153, F236 and F156, rather 
than, as anticipated, involved in interactions with the zinc center. We consider it likely that 
positioning of the thiol moiety in this cavity by the unique ‘hydrophobic wall’ of B2 MBLs 
also explains the high selectivity of Sfh-I for L- over D-BTZs, which is not observed in the B1 
and B3 family members studied in this work. In addition, the carboxylate of bound D-BTZ 
would be positioned differently at the Zn site, requiring different ancillary interactions with the 
protein main chain. In Sfh-I, unlike our observations of BTZ-binding to L1 and IMP-1, the 
more constrained active site provides little room for a second BTZ binding mode. It is likely 
that significant conformational changes within the active site would be required to bind D-
BTZs, resulting in higher Ki’s in vitro, while in the crystalline state these are prevented by 
packing interactions. Taken together, these data clearly indicate that the variation in active-site 
architecture between different MBLs is such that the ability to support more than one mode of 
binding may be necessary to achieve activity towards the full range of targets for even simple 
inhibitor scaffolds. 
Investigation of the activity of BTZs as potential MBL inhibitors was in part prompted 
by their structural similarities to β-lactam substrates. Comparison of L-BTZ:MBL and 
hydrolyzed substrate:MBL structures highlights both differences and similarities in the 
mode(s) of ligand binding (Figure 8). B1 and B3 MBLs bind antibiotic similarly, exemplified 
by the NDM-1:ampicillin (19) (green, Figure 8A) and L1:moxalactam (20) (green, Figure 8B) 
structures, respectively. In particular, in binuclear MBLs K224 (B1) or S223 (B3) interact with 
the carboxylate at C2/C3 of the hydrolyzed -lactam. However, in both cases -lactam binding 
is also characterised by interactions of Zn2 with the β-lactam nitrogen and carboxylate, whereas 
equivalent interactions are not observed in the 1a:MBL complexes. The absence of an 
interaction between the BTZ-nitrogen (a component of the bicyclic ring structure) and Zn2 is 
however consistent with several models of MBL-catalyzed antibiotic hydrolysis that feature 
Zn2-coordination by the β-lactam nitrogen only after the amide bond has been cleaved and the 
β-lactam ring opened (21, 22). On the other hand, BTZ binding involves the thiol group 
bridging Zn1 and Zn2, and displacement of the nucleophilic water (Wat1), while in complexes 
with hydrolyzed antibiotics Wat1 is present (19, 20), albeit with differences in zinc geometry. 
  
These differences are particularly evident in the NDM-1:ampicillin structure [PDB 3Q6X (19)] 
where Wat1 is more tightly bound to a trigonal byprimidal Zn1 (2.1 Å) than Zn2 (2.7 A). In 
comparison, in the native NDM-1 structure [PDB 3SPU (12)] Wat1 is more consistently 
(between the five chains in the ASU) equidistant between Zn1 (tetrahedral geometry) and Zn2. 
1b binding to L1 also involves fewer interactions with Zn2 than hydrolyzed antibiotic (Figure 
8C), although it is notable that Y32, which helps to stabilize inhibitor binding by interaction 
with the BTZ-carboxylate, also stabilises antibiotic binding through interaction with the 
moxalactam carbonyl oxygen (20).  
In comparison to MBL:L-BTZ complexes, (or binding of D-BTZs to L1), 1b binding 
to the B1 MBLs IMP-1 and BcII more closely represents that of hydrolyzed β-lactams. This is 
most evident with respect to interactions involving Zn2 and Lys224, as highlighted by 
comparison of IMP-1:1b and BcII:1b complexes with that of hydrolyzed ampicillin bound to 
NDM-1 (19) (Figure 9A and B, respectively). In particular, both the BTZ and ampicillin 
carboxylate groups interact with Zn2 (2.0-2.2 Å) and hydrogen bond to Lys224 Nε (2.5-2.9Å). 
Furthermore, the bridgehead nitrogen of D-BTZs lies within coordination distance of Zn2 (2.7-
2.8 ± 0.13/0.26 Å), although this interaction is not as strong as the equivalent in the NDM-
1:ampicillin complex involving the β-lactam nitrogen (2.2 Å) (Figure 9C-E). However, 
despite the closer resemblance of their binding to that of antibiotic substrates, comparison of 
Ki values shows D-BTZs to be no more effective B1 MBL inhibitors than the L-BTZs that 
exhibit different binding modes (see Table 1). This may arise from D-BTZ-binding causing 
the energetically unfavourable disruption of the D120-Zn2 interaction. This D120 
rearrangement may be necessary to relieve conformational strain about the Zn2 site arising 
from interaction with bound D-BTZ, or may be a means of relieving steric clashes due to the 
orientation of D-BTZ in the active site imposed by interactions involving the carboxylate group 
and, in particular, positioning of the sulphur atom as a bridging ligand to both zinc ions. 
Similar to B1 and B3 enzymes, structural characterisation of hydrolyzed biapenem binding to 
the B2 MBL CphA (34) (green, Figure 8D) reveals the antibiotic to interact with Zn2 via its 
β-lactam nitrogen atom and carboxylate group, and by hydrogen bonds to Lys224, Thr157 and 
T119. In comparison, in Sfh-I:1a, the BTZ carboxylate group, and not the nitrogen atom, 
interacts with the Sfh-I zinc ion, as well as two residues that are not involved in antibiotic 
binding to CphA, H196 and N233 (blue, Figure 8D). Binding of hydrolyzed biapenem also 
involves residues W87, I153, F236 and F156 of the ‘hydrophobic wall’, a unique structural 
feature of B2 MBLs. These residues also stabilize binding of 1a, specifically the thiol moiety, 
  
indicating that the ‘hydrophobic wall’ is also important in BTZ binding by B2 MBLs (34). 
However, while thiol compounds have been shown as high affinity MBL ligands (35), giving 
rise to the identification of a variety of thiol-based inhibitors, the absence of thiol:Zn2 
interactions in our Sfh-I:BTZ crystal structure supports consideration of other metal binding 
groups, such as carboxylates or phosphonates, in searches for broad-spectrum MBL inhibitors. 
Numerous chemical scaffolds have been explored as candidate MBL inhibitors, in a 
search that is given added impetus by the increasing dissemination of MBLs on mobile genetic 
elements and in clinically significant pathogens. However, studies to date have focussed upon 
relatively restricted numbers of target enzymes, and characterization, particularly at structural 
level, has not in most cases extended to all three enzyme subclasses. Captopril (an angiotensin-
converting enzyme and MBL inhibitor) is the most studied MBL inhibitor, with complexes of 
one or both of its enantiomers described for B1 [BcII (PDB 4C1H (36) and 4C1C (36)), 
BlaB (37), IMP-1 (PDB 4C1G and 4C1F (36)), NDM-1 (38) and VIM-2 (PDB 4C1D and 
4C1E (36))], B2 [CphA (35)] and B3 [L1 (39)] MBLs. Hence we compared the BTZ binding 
modes described here to those of L- and D-captopril, which, like BTZs, feature a carboxylate 
group attached to a ring system and a free thiol group, but lacks the bicyclic organization and 
bridgehead nitrogen of the BTZ scaffold. Similar to BTZ complexes, the free thiol of D- or 
L-captopril bridges the active-site zinc ions of both B1 (IMP-1 and BcII) and B3 (L1) MBLs 
(Figure S10A-E), while the carboxylate interacts with K224 (B1), S223 (B3), or R228 (B1 
VIM-2). However, D-captopril binding to L1 does not involve Y32, as in the L1:1b structure 
(Figure S10D), and unlike 1b binding to BcII and IMP-1 (Figure S10B and S10C), D-
captopril binding to these targets does not feature Zn2-nitrogen or Zn2-carboxylate 
interactions.  
Some other thiol-based inhibitors, such as the thioenolate ML302F (30), or 
mercaptoacetic acids (40), have been noted to make additional interactions with Zn2 through 
their carboxylate groups. Resemblance of D-captopril and BTZ binding is most apparent for 
the B2 enzymes, where D-captopril binds to the active site of CphA through interaction of its 
carboxylate group with the zinc ion (35), as observed in the Sfh-I:1a structure (Figure S10F). 
However, thiol-binding to the Zn2 site of B2 enzymes is possible, as observed previously in a 
CphA:inhibitor co-crystal structure (PDB 3IOF) (41). These data may indicate that, when both 
a thiol and carboxylate are present, the carboxylate-Zn2 interaction may be preferable, possibly 
as a result of the ability of the carboxylate group to make ancillary interactions with the protein 
main chain. 
  
A major hurdle in the development of small molecules as effective countermeasures for 
infections by opportunistic Gram-negative bacteria is the requirement to penetrate the outer 
envelope of the bacterial cell. Many Enterobacteriaceae, and in addition non-fermenting 
species such as A. baumannii or P. aeruginosa, have limited permeability towards many small 
molecule solutes. In a previous investigation we established that BTZs can penetrate Gram-
negative bacteria that express the NDM-1 MBL (17). The present work extends these results 
significantly by demonstrating BTZ inhibition (as evidenced by potentiation of carbapenem 
antimicrobial activity) of MBL activity for enzymes of all three subclasses expressed in E. coli. 
However, to investigate the ability of BTZs to penetrate more challenging organisms, we also 
assessed MBL inhibition in clinical S. maltophilia isolates. S. maltophilia is a versatile 
opportunist pathogen of compromised patients (42), and is attracting increasing attention as a 
pathogen of note in the biology of cystic fibrosis lung disease, with chronic infection identified 
as a risk factor for pulmonary exacerbations (43). S. maltophilia is a notoriously resistant 
organism with increased efflux pump activity, porin reduction, and two inducible -lactamases 
(L1 and L2), that collectively confer resistance to most -lactams (29). Ticarcillin-clavulanate 
is a combination shown to be effective against some S. maltophilia infections (44), but may be 
compromised by -lactamase production (45). Therefore, the ability of BTZs to restore -
lactam efficacy against a nosocomial S. maltophilia isolate indicates potential effectiveness in 
clinically relevant situations, where cross-class inhibition must extend to extensively drug-
resistant physiological strains. 
 In closing, we report BTZs achieve cross-class MBL inhibition despite the structural 
diversity and zinc requirements of the different enzyme targets. The ability of the unique BTZ 
scaffold to bind in multiple orientations is likely due to the substrate-like design that is 
decorated with two strong metal-binding groups (-SH and -COOH). Indeed, the multiple 
binding modes possible for B1 and B3 enzymes accord with the broad substrate spectrum of 
these enzymes, while the B2 MBL, which shows preference for carbapenem substrates, shows 
some stereochemical preference. BTZs therefore provide a novel, efficient strategy for cross-
class MBL inhibition, show activity against target bacterial pathogens as well as in vitro, and 
thus justify efforts at further improvement to enhance potency and clinical applicability. 
 
  
  
Materials and Methods 
Synthesis of bisthiazolidines 
1a (L-CS319; (2R,5S,8R)-8-carboxylate-2-mercaptomethyl-1-aza-3,6-dithiobicyclo[3.3.0] 
octane); 1b (D-CS319; (2S,5R,8S)-8-carboxylate-2-mercaptomethyl-1-aza-3,6-
dithiobicyclo[3.3.0] octane); 2a (L-VC26; (2R,5S,8R)-2-mercaptomethyl-7-dimethyl-8-
carboxylate-1-aza-3,6-dithiobicyclo[3.3.0] octane); and 2b (D-VC26; (2S,5R,8S)-2-
mercaptomethyl-7-dimethyl-8-carboxylate-1-aza-3,6-dithiobicyclo[3.3.0] octane) were 
synthesised as previously described (18). The L- and D- notation thus refers to the 2R,5S,8R 
and 2S,5R,8S chiralities of the BTZs, respectively. 
Purification of soluble MBLs. 
IMP-1, L1 and Sfh-I lacking the first 21 amino acids were cloned into pOPINF vectors (46) 
resulting in N-terminally His6-tagged protein cleavable with 3C protease. BcII was cloned into 
the pET28a vector (Novagen) using NdeI and SalI restriction sites, resulting in N-terminally 
His6-tagged protein cleavable with thrombin. For IMP-1, L1 and Sfh-I production, E. coli 
SoluBL21 (DE3) cells (Genlantis) bearing pOPINF were grown at 37 °C in auto-induction 
terrific broth media (Formedium) for 8 h then left overnight at 20 °C. BcII was overexpressed 
in E. coli BL21(DE3), grown at 37 °C in LB medium to A600 0.6, when 0.5 mM IPTG and 0.5 
mM ZnSO4 were added (16 h, 18 °C). Cells were harvested by centrifugation (6,500 xg, 
10 min).  
For L1, cells were resuspended in 50 mM HEPES pH 8.0, 400 mM NaCl, Complete 
EDTA-free protease inhibitor mixture (Roche), 10 µM ZnCl2 and broken by two passages 
through a cell disruptor (30,000 psi). After centrifugation (100,000 x g, 1h), supernatant (plus 
8 mM imidazole) was incubated 2 hrs with Ni-NTA resin (Qiagen). 1 mM β-mercaptoethanol 
was included in all subsequent buffers. Protein bound resin was washed in Buffer A (50 mM 
Tris pH 7.5, 400 mM NaCl, 10 µM ZnCl2) plus 10 mM imidazole, then with the same buffer 
plus 0.1% Triton X-100. Resin was further washed in Buffer A plus 20 mM imidazole and 
protein eluted in 50 mM Tris pH 7.5, 200 mM NaCl, 10 µM ZnCl2, 400 mM imidazole.  
Imidazole was reduced to 10 mM in an Amicon 10 kDa molecular weight cut-off (mwco) 
concentrator. The tag was removed by 3C protease cleavage (4 °C, overnight) and capture on 
Ni-NTA resin. L1 was subsequently loaded onto a Superdex S200 column equilibrated in 10 
mM Tris pH 7.0, 100 mM NaCl, 100 µM ZnS04. Peak fractions were concentrated to 23 mg/ml. 
For crystallisation, L1 protein was supplemented with 5 mM ZnSO4. IMP-1 was purified 
  
similar to L1, except 1 mM TCEP (rather than β-mercaptoethanol) was included in all buffers, 
and protein loaded onto a Superdex S75 column equilibrated in 50 mM Tris pH 7.5, 150 mM 
NaCl, 100 µM ZnCl2, 1 mM TCEP and concentrated to 25 mg/ml. Sfh-I was purified as L1, 
except protein was loaded on to a Superdex S75 column equilibrated in 50 mM HEPES pH 7.0 
and concentrated to 15 mg/ml. For BcII, cells were re-suspended in Buffer B (50 mM Tris pH 
8.0, 200 mM NaCl) supplemented with 10 µg/mL DNAse, 4 mM MgCl2, and 2 mM 
phenylmethylsulfonyl fluoride (PMSF) and disrupted by sonication. After centrifugation (60 
min, 15,000 g) and supernatant loaded on to Ni-sepharose resin equilibrated with Buffer A. 
The column was washed with 100 mL of Buffer B and BcII was eluted with Buffer B plus 500 
mM imidazole using a linear gradient (0-100% Buffer B, over 100 ml). The his-tag was 
removed with thrombin and capture on Ni-sepharose resin. Flow-through (cleaved BcII) was 
diluted (1:5) in Buffer C (100 mM HEPES pH 7.0, 1 mM ZnSO4) and loaded on to CM-
sepharose resin equilibrated with Buffer C. The column was washed with 100 mL of Buffer C 
and BcII was eluted with Buffer C plus 400 mM NaCl, with a purity > 95%, as determined by 
SDS-PAGE. Protein was concentrated to 15 mg/ml using Centricon ultrafiltration devices 
(Millipore, Bedford, MA, USA) and exchanged into 10 mM Tris-HCl pH 7, 50 mM NaCl, 1 
mM DTT, and 1 mM ZnSO4.  
GOB-18 was purified cytoplasmically, and reconstituted in its fully active monozinc 
form, as previously described (27). 
  
Enzyme assays  
Inhibition constants (Ki) were determined by following imipenem hydrolysis at 300 nm 
absorbance (JascoV-670 spectrophotometer) in Buffer C (10 mM HEPES pH 7.5, 0.2 M NaCl, 
50 µg/mL BSA; B1 and B3 enzymes) or Buffer C plus 20 µM ZnSO4 (B2 Sfh-I). BTZs were 
dissolved in DMSO (30 mM) and diluted in reaction buffer to the desired concentration. The 
presence of 1% DMSO did not alter the enzyme activity. Assays were initiated by enzyme 
addition to the substrate and inhibitor mixture. Ki’s were determined by data fitting to the 
Competitive Inhibition Model implemented in GraphPad Prism 5.0. 
 
In vitro time-kill study. 
  
Escherichia coli DH5α carrying the pMBLe plasmid (17) expressing MBLs BcII, IMP-1, Sfh-
I and GOB-18 were cultured overnight at 37 ºC in Mueller Hinton Broth (MHB) supplemented 
with 25 mg/L gentamycin. 1.5 µl of the overnight cultures were inoculated in 1 mL MHB 
supplemented with 100 µM IPTG to obtain a bacterial suspension of approximately 106 
CFU/mL. To examine the effects of the novel BTZs compounds on bacterial growth, bacterial 
suspensions were grown at 37 ºC under different conditions: MHB alone (growth control), or 
supplemented with 0.4% DMSO (growth control), sub-lethal imipenem concentrations, 100 
mg/L of each inhibitor, or a combination of imipenem and inhibitor. Samples (10 µl) were 
removed at intervals of 100, 300 and 500 min of exposure, and serial dilutions performed on 
MHB. Viable cell numbers were determined by spotting 20 µl of each dilution on Muller 
Hinton Agar (MHA). Plates were incubated (37 ºC overnight), and colonies counted. Results 
are the mean of three biological replicates. Assays using a clinical isolate of S. maltophilia 
(strain C1: L1 and L2 producer) were performed similarly except samples were taken after 4, 
8 and 12 hours of treatment.  
 
Crystallization and structure Determination.  
L1 and Sfh-I were crystallized as previously described (14, 15). IMP-1 was crystallized using 
sitting drop vapor diffusion in CrysChem24 well plates (Hampton Research) at 18 °C. Drops 
were formed by mixing 1 µl protein solution with 1 µl crystallization reagent (0.1 M sodium 
cacodylate pH 6.0, 0.2 M sodium acetate, 25% PEG8000) and equilibrated against 500 µl. 
Crystals grew to maximum size in seven days. BcII was crystallized using hanging-drop vapour 
diffusion in 24-well plates (Hampton Research) at 20 °C. Drops were formed by mixing 1 µl 
protein solution with 1 µl crystallization reagent (180 mM K2SO4, 20 % PEG 3350, 1 mM 
DTT, and 1 mM ZnSO4) and equilibrated against 1 ml. Crystals grew to maximum size within 
3–5 days.  
Inhibitor bound complexes were obtained by soaking crystals for 15–60 min in 2-5 mM 
inhibitor dissolved in cryoprotectant [L1: 0.05 M HEPES pH 7.5, 1.75 M (NH4)2SO4, 1.25% 
PEG400, 25% glycerol, 2 mM TCEP; IMP-1: 0.1 M sodium cacodylate, 0.15 M sodium 
acetate, 25% ethylene glycol, 15% PEG8000, 2 mM TCEP, 50 µM ZnCl2; Sfh-I: 0.02 M 
HEPES pH7.5, 0.12 M sodium acetate, 14% PEG3350, 20% glycerol, 2 mM TCEP; BcII: 
reservoir plus 20% glycerol]. IMP-1 native crystals were cryoprotected by soaking (1 min) in 
IMP-1 cryoprotectant. Crystals were looped and flash-frozen in liquid nitrogen. Diffraction 
  
data were collected at 100K on beamlines I02, I03, I04, I04-1 or I24 (Diamond Light Source, 
UK) or on a high-flux Rigaku RAXIS IV++ in-house X-ray generator (BcII, Los Alamos 
National Laboratory). Data sets were indexed and integrated using XDS (47), iMosflm (48) or 
HKL2000 (49) and scaled using Aimless in CCP4 (50) or HKL2000 (49). Crystals were not 
prone to radiation damage in all cases and relatively high Rmerge values, compared to high I/σI 
values, are due to the high redundancy of the data, or in the case of BcII:1b due to the collection 
of data on a home source. Structures were phased by molecular replacement with Phaser (51) 
using as starting models PDB 3I13 (52) (BcII), 1SML (15) (L1), 1DD6 (10) (IMP-1) or 3SD9 
(14) (Sfh-I). Structures were completed by iterative rounds of manual model building in Coot 
(53) and refinement in Phenix (54) or Refmac5 (55). Sfh-I crystals were pseudo-merohedrally 
twinned [twin law h,-k,-l, determined by Xtriage (54)], so the Sfh-I model was completed with 
twin refinement in Refmac5. Omit maps were calculated from the final model after removal of 
the ligand and refinement in Phenix (L1, IMP-1, BcII) or Refmac (Sfh-I). Ligand structures 
and geometric restraints were calculated with PRODRG (56) or Phenix eLBOW (57). Structure 
validation was assisted by Molprobity (58), SFCHECK (59), and Phenix. Figures were 
prepared using PyMol (60). Root mean square deviations (RMSDs) were calculated over Cα 
atoms aligned using PDBeFold (61). Ligand buried surface areas were calculated using 
PDBePisa (62). 
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Figure Legends 
Fig. 1. Architecture of B1, B2 and B3 metallo-β-lactamases. 
The common αββα fold of representative MBLs is colored from N- (light blue) to C-terminus 
(light red), and is shown alongside a close up view of the active-site (boxed). Zinc ions (gray) 
and water molecules (red) are represented as spheres. Zinc coordination bonds are shown as 
gray dashes, with the corresponding residues (labelled) shown as sticks. 
(A) B1 BcII (PDB 4C09)  
(B) B2 Sfh-I (PDB 3SD9)  
(C) B3 L1 (PDB 1SML) 
 
Fig. 2. Chemical structures of bisthiazolidine inhibitors. 
Bisthiazolidines 1a (L-CS319, blue), 1b (D-CS319, gray), 2a (L-VC26, orange) and 2b (D-
VC26, cyan). 
 
Fig. 3. Bisthiazolidines restore the in vitro activity of imipenem against a 
Stenotrophomonas maltophilia clinical isolate. 
Bacteria were grown at sub-lethal concentrations of a mixture of ticarcillin (TIC, 64 µg/mL) 
and clavulanate (CLV, 2 µg/mL) or in combination with 100 µg/mL of each compound. 
Viable cells were recovered at 4, 8 and 12 hours. Results shown are the mean of three 
biological replicates +/- SD. 
 
Fig. 4. L-bisthiazolidine binding to B1 (IMP-1) and B3 (L1) metallo-β-lactamases. 
Close up view of IMP-1 and L1 active sites with bound L-BTZ (sticks, colored as Figure 2). 
Protein main chain is colored from N- (light blue) to C-terminus (light red). Residues which 
interact with the zinc ions (Zn1 and Zn2, gray spheres) are shown as sticks (colored as main 
chain), while hydrophobic residues that stabilize BTZ binding are shown as gray sticks. 
IMP-1 K224 and L1 S223 (labelled) interact with the BTZ carboxylate. 
(A) 2a bound to B1 IMP-1. Protein-zinc interactions are shown as gray dashes and 
BTZ-protein or BTZ-zinc interactions are shown as yellow dashes.  
  
(B) 1a bound to B3 L1. Interactions shown as in A. 
(C) Superposition of IMP-1:2a (orange) and L1:1a (blue). BTZ-protein or BTZ-zinc 
interactions are shown as dashes colored orange (IMP-1:2a) or blue (L1:1a). 
 
Fig. 5. 1a binding to Sfh-I and concomitant active-site conformational changes. 
Active-site zinc ions (gray spheres) and water molecules (red spheres) are labelled. 
(A) 1a (blue) bound in the active site of B2 Sfh-I (main chain colored as Figure 1). 
Hydrophobic residues, on the α3 region and within the active site, involved in binding 1a are 
shown as gray sticks. The 1a carboxylate bridges N233 and H196 (sticks). Residues involved 
in binding the active-site zinc ion (Zn2, gray sphere) and water (Wat2, red sphere) are 
represented as sticks. Interactions of 1a with the protein main chain or Zn2 are shown as 
yellow dashes. Protein-zinc and protein-water interactions are shown as gray dashes. 
(B) Superposition of Sfh-I:1a (blue) with unliganded, native Sfh-I (PDB 3SD9, green). 
Interactions of H118 and H196 with the BTZ or Wat2 are shown as dashes. 
 
Fig. 6. 1b binding to B3 MBL L1. 
A water molecule (red sphere) mediates the interaction of Y32 (sticks, labelled) with the D-
BTZ carboxylate while S223 (sticks, labelled), which binds 1a, is not involved. Hydrophobic 
and zinc-binding residues represented as Figure 4.  
(A) 1b (gray) bound in the active site of B3 L1 (colored as Figure 4). Interactions shown as 
Figure 4.  
(B) Superposition of L1:1b (gray) with L1:1a (blue). Interactions between the BTZ and 
protein are shown as gray or blue dashes, according to their respective structures. 
(C) 2b (cyan) bound to B3 L1, represented as B. 
 
Fig. 7. 1b binding to B1 MBLs BcII and IMP-1. 
1b bound in the active of B1 MBLs (A) IMP-1 and (B) BcII (colors and interactions as 
Figure 4). In both A and B, K224 binds the 1b carboxylate and the D120 – Zn2 coordination 
is disrupted. (C) Superposition of IMP-1:1b (gray; zinc ions light gray) with unliganded, 
native IMP-1 (green; zinc ions, dark gray). Binding causes movement of Zn2, and loss of the 
  
D120 – Zn2 interaction.  
(D) Superposition of BcII:1b (gray; zinc ions light gray) with unliganded, native BcII (PDB 
4C09 green; zinc ions, dark gray). Binding is similar to C, causing the same rearrangements 
within the active site. 
 
Fig. 8. Comparisons of the mode of binding between bisthizolidines and hydrolysed 
antibiotics. 
Superpositions of (A) IMP-1:1a (orange; zinc ions, light gray) with NDM-1:hydrolyzed 
ampicillin (PDB 3Q6X, green; zinc ions, dark gray); (B) L1:1a (blue; zinc ions, light gray) 
with L1:moxalactam (PDB 2AIO, green; zinc ions, dark gray); (C) L1:1b (gray; zinc ions, 
light gray) with L1:moxalactam (as B); (D) Sfh-I:1a (gray; zinc ions, light gray) with 
CphA:biapenem (PDB 1X8I, green; zinc ions, dark gray).  
 
Fig. 9. 1b binding to B1 MBLs IMP-1 and BcII closely resembles binding of hydrolysed 
antibiotic. 
Superpositions of NDM-1:ampicillin (green) with (A) IMP:1b and (B) BcII:1b (gray; zinc 
ions, light gray). The modes of binding and ligand-protein/zinc interaction distances are 
shown in schematic representation for (C) NDM-1:hydrolysed ampicillin; (D) IMP-1:1b and 
(E) BcII:1b. 
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Table 1. In vitro competitive inhibition of MBLs by bisthiazolidines  
   Inhibition constants (Ki / µM)  
MBL 
subclass 
Enzyme Substrate 1a 1b 2a 2b Reference 
B1 NDM-1 Imipenem 7 ± 1 19 ± 3 18 ± 3 12 ± 1 (17) 
 VIM-2 Imipenem 3.7 ± 0.3 5.4 ± 0.4 3.8 ± 0.2 14 ± 1 (18) 
 IMP-1 Imipenem 8 ± 2 6 ± 1 15 ± 3 14 ± 3 - 
 BcII Imipenem 36 ± 2 53 ± 5 32 ± 3 84 ± 6 - 
B2 Sfh-I Imipenem 0.26 ± 0.03 26 ± 3 0.36 ± 0.04 29 ± 3 - 
B3 L1 Imipenem 12 ± 1 10 ± 1 11 ± 2 10 ± 1 - 
 GOB-18 Imipenem 41 ± 4 30 ± 2 31 ± 2 10 ± 1 - 
 
  
  
Supporting Information 
SI Results 
High resolution crystal structure of native, uncomplexed di-zinc IMP-1 
At 3.1 Å, in space group P21 [one molecule in the asymmetric unit (ASU)], PDB 1DDK 
represented the highest resolution structure of uncomplexed di-zinc IMP-1. At this resolution, 
it was not possible to model important features such as the nucleophilic water. We therefore 
sought to obtain a high resolution structure of uncomplexed di-zinc IMP-1.  
 We have solved the structure of native di-zinc IMP-1 in the same space group and cell 
dimensions (P212121, 4 molecules in the ASU) as the BTZ:IMP-1 complexes, allowing direct 
comparison between structures. Resolution extended to 1.98 Å (Table S1) and the model 
includes residues (standard BBL numbering) 38-298 (chain A, average B-factor 34.3 Å2), 36-
298 (chain B, average B-factor 35.1 Å2), 39-302 (chain C, average B-factor 34.9 Å2), 39-298 
(chain D, average B-factor 53.0 Å2). Chain B also includes the N-terminal residues G and P, 
left over after 3C protease cleavage of the hexa-histidine tag. The quality of the density allowed 
modelling of the nucleophilic water in all four chains (B-factors 26.6 Å2, 25.7 Å2, 23.74 Å2 and 
30.46 Å2, chains A-D, respectively), and confident placement of the L3 loop (residues 61-65) 
with B-factors 56.2 Å2, 37.1 Å2, 40.8 Å2 and 64.1 Å2 (chains A-D, respectively). 
 Uncomplexed di-zinc IMP-1 has the same overall fold as the previous IMP-1 structure 
(PDB 1DDK) with RMSDs 0.52 Å (chain A, over 218 Cα atoms), 0.58 Å (B, 218), 0.63 Å (C, 
217) and 0.47 Å (D, 217). Zn1-Zn2 distances (± 0.19 Å) are 3.42 Å (chain A), 3.36 Å (B), 3.34 
Å (C), 3.37 Å (D) compared to 1DDK Zn1-Zn2 3.29 Å (± 0.65 Å). The nucleophilic water 
bridges the active-site zincs and over the four chains has refined consistently closer (± 0.19 Å) 
to Zn2 (1.87 Å, 1.93 Å, 1.91 Å and 1.85 Å) than Zn1 (2.43 Å, 2.17 Å, 2.11 Å, 2.26 Å), with a 
second water molecule liganding Zn2 (2.27 Å, chain A). This results in tetrahedral (Zn1) and 
distorted trigonal byprimidal (Zn2) zinc geometries, common to B1 MBLs. 
 Confirming the flexible nature of the L3 loop, it adopts a different conformation in 
chain C compared to chains A, B and D where it is present in a more ‘open’ conformation than 
the three other chains (a c. 5 Å shift, Figure S11). This could be due to the fact the L3 loop 
forms extensive crystal contacts between neighbouring molecules in the ASU, resulting in 
similar L3 loop B-factors to the protein main chain (particularly for chains B and C). 
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Table S1. Data collection and refinement statistics. 
MBL IMP-1 BcII Sfh-I L1 
MBL class  B1  B1 B2  B3  
Inhibitor 1b 2a 
un-
complexed 
1b 1a 1a 1b 2b 
Data collection         
Space group P2
1
2
1
2
1
 P212121 P2
1
2
1
2
1
 C21 P21 P6422 P6422 P6422 
Molecules/ASU 4 4 4 1 2 1 1 1 
Cell dimensions         
    a, b, c (Å) 48.56, 
77.70, 
261.89 
49.05, 
78.45, 
260.61 
49.19, 
78.00, 
260.13 
53.08, 
61.28, 
69.51 
32.77, 
86.70, 
72.23 
104.98, 
104.98, 
98.47 
104.96, 
104.96, 
98.83 
105.13, 
105.13, 
98.17 
 ()  90.0, 90.0, 
90.0 
90.0, 90.0, 
90.0 
90.0, 90.0, 
90.0 
90.0, 
93.04, 90.0 
90.0, 
90.09, 90.0 
90.0, 90.0, 
120.0 
90.0, 90.0, 
120.0 
90.0, 90.0, 
120.0 
Wavelength 0.9686 0.92 0.96862 1.5418 0.97949 0.97623 0.9686 0.97949 
Resolution (Å)* 37.24 – 
2.30 (2.38 
– 2.30)  
29.82 – 
2.30 (2.38 
– 2.30)  
35.57 – 
1.98 (2.03 
– 1.98) 
40.09 - 
1.80 (1.86-
1.80) 
19.42 – 
1.30 (1.32 
– 1.30) 
30.87 – 
1.63 (1.66 
– 1.627) 
28.97 – 
1.84 (1.88 
– 1.84) 
30.35 – 1.8 
(1.84 – 
1.80) 
Rmerge 0.190 
(1.530) 
0.109 
(0.521) 
0.200 
(0.779) 
0.272 
(0.760) 
0.118 
(0.413) 
0.084 
(0.65) 
0.213 
(0.778) 
0.180 
(0.858) 
I / I 11.60 
(3.10) 
18.3 (4.2) 5.8 (2.2) 4.0 (1.30) 7.6 (3.6) 41.04 (6.0) 16.9 (5.6) 21.69 
(4.29) 
Completeness (%) 100 (99.8) 99.9 (99.9) 99.0 (98.0) 97.8 (81.7) 97.6 (95.5) 99.7 (94.1) 99.4 (90.3) 100 (100) 
Redundancy 17.7 (18.1) 10.3 (9.9) 9.5 (8.3) 4.2 (2.7) 5.8 (5.9) 65.3 (27.3) 37.9 (32.2) 33.8 (34.9) 
         
Refinement         
Resolution (Å) 37.24 – 
2.30 (2.35 
– 2.30) 
29.82 – 
2.30 (2.35 
– 2.30) 
35.57 – 
1.98 (2.01 
– 1.98) 
40.09 – 
1.80 (1.85 
– 1.80) 
19.42 – 
1.30 (1.33 
– 1.30) 
30.87 – 
1.63 (1.67 
– 1.63) 
28.97 – 
1.84 (1.91 
– 1.84) 
30.35 – 
1.80 (1.86 
– 1.80) 
No. reflections 45125 45814 69452 19247 91618 40522 28142 30208 
Rwork / Rfree 17.77 
(23.76) / 
22.03 
(26.90) 
18.20 
(24.06) / 
22.20 
(26.00) 
17.21 
(24.55) / 
20.45 
(27.52) 
19.3 
(38.40) / 
24.4 
(43.10) 
16.02 
(27.20) / 
18.86 
(30.50) 
15.74 
(21.86) / 
18.18 
(24.26) 
14.79 
(20.27) / 
19.49 
(26.11) 
16.55 
(25.07) / 
19.57 
(25.50) 
Coordinate error 
(Å)1 
0.26 0.23 0.19 0.13 0.03 0.14 0.17 0.18 
No. atoms         
    Protein 6888 6870 6892 1718 3717 2012 2006 2015 
    Solvent/Zn 338 337 510 140 605 340 337 283 
    Inhibitor 52 (4) 45 (3) - 13 (1) 26 (2) 13 (1) 13 (1) 15 (1) 
B-factors         
    Protein 43.45 39.66 39.64 28.71 11.02 25.72 21.64 25.15 
    Solvent/Zn 42.17 37.88 44.52 34.64 20.74 38.94 36.0 36.4 
    Inhibitor 44.00 66.74 - 45.32 13.73 54.02 38.45 42.98 
R.m.s. deviations         
    Bond lengths 
(Å) 
0.009 0.008 0.008 0.017 0.0110 0.016 0.007 0.008 
    Bond angles () 1.18 1.18 1.12 1.871 1.5689 1.573 1.04 1.05 
Ramchandran (%)         
    Outliers 0.0 0.0 0.5 0.32 0.4 0.0 0.0 0.0 
    Favoured 97.7 97.2 97.4 96.43 97.0 96.4 96.4 95.6 
*Values in parentheses correspond to the highest-resolution shell 
1Maximum-likelihood coordinate error 
   
  
Table S2. Ligand validation statistics 
Protein 
MBL 
subclass 
Chain Ligand LLDF1 RSR2 RSCC3 
IMP-1 B1 C 1b -1.41 0.08 0.991 
IMP-1 B1 C 2a 0.15 0.15 0.962 
BcII B1 N/A 1b 0.36 0.13 0.930 
Sfh-I B2 A 1a 0.19 0.06 0.949 
L1 B3 N/A 1a 1.88 0.16 0.924 
L1 B3 N/A 1b 3.44 0.18 0.918 
L1 B3 N/A 2b 1.24 0.15 0.951 
1Local ligand density fit as reported by PDB validation 
2Real space R-value as reported by PDB validation 
3Real-space density correlation coefficient as reported by Phenix 
  
  
Table S3. Zinc distances in B1 and B3 MBL active sites. 
  Distances (Å) 
   BTZ-SH to Nucleophilic water to 
Protein Ligand Zn1-Zn2 Zn1 Zn2 Zn1 Zn2 
IMP-1 Native3 3.34 - - 2.11 1.91 
1b4 3.64 2.31 2.28 - - 
2a4 3.67 2.43 2.26 - - 
L1 Native1 3.46 - - 1.88 2.06 
1b 3.89 2.37 2.04 - - 
1a 3.86 2.27 2.22 - - 
2b 3.80 2.34 1.96 - - 
BcII Native2 3.50 - - 2.33 2.34 
1b 3.80 1.95 1.99 - - 
1PDB 1SML 
2PDB 4C09 
3Chain C 
4Chain A 
 
 
 
 
  
  
 
